IMAX Stock Slides After-Hours As CEO Goes On Temporary Leave Of Absence

• While Gelfond receives medical care and recovers, he will not be participating in any public or private events for the company, the statement said. 
• IMAX is a leader in entertainment technology, delivering immersive cinematic experiences through proprietary software, architecture, and projection systems.
• Earlier in the month, Goldman Sachs raised the firm's price target on Imax to $41 from $37 and kept a ‘Neutral’ rating on the shares. 

Imax Corp. (IMAX) on Monday announced that CEO Richard Gelfond would be on a temporary medical leave of absence as he undergoes treatment for pneumonia.

Shares in the company fell 2% during extended hours of trading. 

While Gelfond receives medical care and recovers, he will not be participating in any public or private events for the company, the company said. 

Consistent with its operating plan in the event of Gelfond’s temporary absence, the firm’s senior executives are executing their day-to-day responsibilities in coordination with each other and Board Chairman Darren Throop, with regular communication with the full board of directors. 

“We have a strong, deeply experienced senior executive team who are fully engaged, providing regular updates to the Board, and remain focused as always on the continued growth and success of IMAX. We are all wishing Rich well and a full and speedy recovery,” Throop said. 

About IMAX

IMAX is a leader in entertainment technology, delivering immersive cinematic experiences through proprietary software, architecture, and projection systems.

Headquartered in New York, Toronto, and Los Angeles, IMAX operates 1,864 systems across 91 countries and territories as of December 31, 2025.

Recent Analyst Actions

Earlier in the month, Goldman Sachs raised the firm's price target on Imax to $41 from $37 and kept a ‘Neutral’ rating on the shares. 

Late in February, B. Riley analyst Drew Crum raised the firm's price target on Imax to $46 from $44 and kept a ‘Buy’ rating on the shares. 

JPMorgan raised the firm's price target on Imax to $48 from $47 and kept an ‘Overweight’ rating on the shares. The company reported another quarter with revenue and margin ahead of consensus, the analyst had told investors in a research note.

How Did Retail Traders React?

Retail sentiment around IMAX stock trended in ‘bearish’ amid ‘normal’ message volume. 

Shares in the company have risen almost 2% so far in 2026.